These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 22549762)

  • 1. Paliperidone for irritability in adolescents and young adults with autistic disorder.
    Stigler KA; Mullett JE; Erickson CA; Posey DJ; McDougle CJ
    Psychopharmacology (Berl); 2012 Sep; 223(2):237-45. PubMed ID: 22549762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paliperidone for irritability in autistic disorder.
    Stigler KA; Erickson CA; Mullett JE; Posey DJ; McDougle CJ
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):75-8. PubMed ID: 20166801
    [No Abstract]   [Full Text] [Related]  

  • 3. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.
    Stigler KA; Diener JT; Kohn AE; Li L; Erickson CA; Posey DJ; McDougle CJ
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):265-74. PubMed ID: 19519261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective open-label trial of paliperidone monotherapy for the treatment of bipolar spectrum disorders in children and adolescents.
    Joshi G; Petty C; Wozniak J; Faraone SV; Spencer AE; Woodworth KY; Shelley-Abrahamson R; McKillop H; Furtak SL; Biederman J
    Psychopharmacology (Berl); 2013 Jun; 227(3):449-58. PubMed ID: 23397049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study.
    Wake R; Miyaoka T; Inagaki T; Furuya M; Ieda M; Liaury K; Kishi K; Horiguchi J
    J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):329-36. PubMed ID: 23782127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.
    Turkoz I; Bossie CA; Lindenmayer JP; Schooler N; Canuso CM
    BMC Psychiatry; 2011 Feb; 11():21. PubMed ID: 21299844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder.
    Marcus RN; Owen R; Kamen L; Manos G; McQuade RD; Carson WH; Aman MG
    J Am Acad Child Adolesc Psychiatry; 2009 Nov; 48(11):1110-1119. PubMed ID: 19797985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study.
    Marcus RN; Owen R; Manos G; Mankoski R; Kamen L; McQuade RD; Carson WH; Corey-Lisle PK; Aman MG
    J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):229-36. PubMed ID: 21663425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder.
    Owen R; Sikich L; Marcus RN; Corey-Lisle P; Manos G; McQuade RD; Carson WH; Findling RL
    Pediatrics; 2009 Dec; 124(6):1533-40. PubMed ID: 19948625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial.
    Ghaleiha A; Mohammadi E; Mohammadi MR; Farokhnia M; Modabbernia A; Yekehtaz H; Ashrafi M; Hassanzadeh E; Akhondzadeh S
    Paediatr Drugs; 2013 Dec; 15(6):505-14. PubMed ID: 23821414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
    Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
    J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial.
    Aman M; Rettiganti M; Nagaraja HN; Hollway JA; McCracken J; McDougle CJ; Tierney E; Scahill L; Arnold LE; Hellings J; Posey DJ; Swiezy NB; Ghuman J; Grados M; Shah B; Vitiello B
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):482-93. PubMed ID: 26262903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paliperidone palmitate in a child with autistic disorder.
    Kowalski JL; Wink LK; Blankenship K; Habenicht CD; Erickson CA; Stigler KA; McDougle CJ
    J Child Adolesc Psychopharmacol; 2011 Oct; 21(5):491-3. PubMed ID: 22040196
    [No Abstract]   [Full Text] [Related]  

  • 14. Loxapine add-on for adolescents and adults with autism spectrum disorders and irritability.
    Hellings JA; Reed G; Cain SE; Zhou X; Barth FX; Aman MG; Palaguachi GI; Mikhnev D; Teng R; Andridge R; Logan M; Butler MG; Han JC
    J Child Adolesc Psychopharmacol; 2015 Mar; 25(2):150-9. PubMed ID: 25782098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Hajizadeh-Zaker R; Ghajar A; Mesgarpour B; Afarideh M; Mohammadi MR; Akhondzadeh S
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):74-81. PubMed ID: 29027815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with paliperidone in children with behavior disorders previously treated with risperidone: an open-label trial.
    Fernández-Mayoralas DM; Fernández-Jaén A; Muñoz-Jareño N; Calleja-Pérez B; Fernández-Perrone AL; Arribas SL
    Clin Neuropharmacol; 2012; 35(5):227-30. PubMed ID: 22935606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms.
    Canuso CM; Turkoz I; Sheehan JJ; Bossie CA
    J Affect Disord; 2010 Jan; 120(1-3):193-9. PubMed ID: 19552963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
    Hough D; Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M
    Schizophr Res; 2010 Feb; 116(2-3):107-17. PubMed ID: 19959339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ziprasidone in adolescents with autism: an open-label pilot study.
    Malone RP; Delaney MA; Hyman SB; Cater JR
    J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):779-90. PubMed ID: 18315450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paliperidone extended release: a review of its use in the management of schizophrenia.
    Chwieduk CM; Keating GM
    Drugs; 2010 Jul; 70(10):1295-317. PubMed ID: 20568835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.